注射用胰激肽原酶治疗糖尿病肾病高凝状态探讨

目的:探讨注射用胰激肽原酶治疗糖尿病肾病(diabetic nephropathy,DN)的疗效及合理用法。方法:对24例糖尿病肾病患者(DN组)注射胰激肽原酶,对8例健康者(对照组)空腹分次采肘静脉血,应用Sonoclot分析仪及酶联免疫法动态检测所采静脉血标本,再对所得数据进行分析。结果:给药后4 h,DN组全部患者凝血速率(CR)值均低于给药前,给药后12 h,有9例(37.5%)低于给药前,给药后24 h仅有6例(25.0%)低于给药前。DN组玻璃珠激活的凝血时间(gbACT)与活化部分凝血激酶时间(aPrr)呈正相关,CR与纤维蛋白原(FIB)呈正相关,PF1+2与CR呈正相关,PF与血小板数(PLT)呈正相关,GMP-140与PF之间无相关。结论:注射用胰激肽原酶改善糖尿病肾病微循环障碍有确切疗效,但其有效剂量和有效给药方法还需要进一步研究。

The discussion of the treatment in diabetie nephropathy for high pour-point state with pantcreatic shocr peptule enzyme by injecting

Objective To investigate the injection of pancreatic kallikrein treatment of diabetic nephropathy（diabetic nephropathy,DN） of the efficacy and reasonable usage.Methods 24 patients with diabetic nephropathy（DN group） injected after pancreatic kallikrein and 8 healthy subjects（control group） fasting blood graded elbow mining application Sonoclot analyzer and dynamic detection of enzymelinked immunosorbent assay vein adopted Blood samples were analyzed the data again.Results After administration of 4 h,DN group all blood coagulation rate（CR） were lower than before administration,after administration 12 h,9 patients（37.5%） lower than before administration,after administration of 24 h only 6 cases（25.0%） lower than premedication.DN group of glass beads activated clotting time（gbACT） and activated partial thromboplastin time（aPrr） was positively correlated,CR and fibrinogen（FIB） was positively correlated,PF1＋2 with CR was positively correlated,PF and platelet count（PLT） was positively related,GMP.No correlation between the 140 and PF.Conclusion The injection of pancreatic kallikrein microcirculation in diabetic nephropathy there is a genuine effect,but the effective dose and effective drug delivery method also needs further study.